Search
ALKS 29
go.drugbank.com/drugs/DB05723ExperimentalALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
Strontium malonate
go.drugbank.com/drugs/DB05732InvestigationalStrontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.
MIV-701
go.drugbank.com/drugs/DB05736ExperimentalMIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Varespladib methyl
go.drugbank.com/drugs/DB05737InvestigationalVarespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Categories: Heterocyclic Compounds, 2-RingRPI-78M
go.drugbank.com/drugs/DB05740ExperimentalOther neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
CRx-139
go.drugbank.com/drugs/DB05744ExperimentalIt is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.
Andrographolide
go.drugbank.com/drugs/DB05767InvestigationalAndrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China.
Synonyms: 3α,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid γ-LactoneRabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Categories: Heterocyclic Compounds, 2-RingTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: T-DM1